Company intelligence / Profile preview
AGeM Bio
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
AGeM Bio is a preclinical-stage biotechnology company dedicated to reversing the biological effects of aging through advanced epigenetic reprogramming. Spun out from the laboratory of Dr. George Church at Harvard Medical School, the company leverages its proprietary Aging Genome Engineering and Modulation (AGeM) platform to restore youthful cellular function. By precisely delivering specific transcription factors, AGeM Bio aims to reset the epigenetic clock of aged or diseased tissues without inducing pluripotency. The company's initial therapeutic focus includes age-related ophthalmic conditions and neurodegenerative diseases. AGeM Bio represents a leading effort in the emerging field of longevity medicine, seeking to transform how age-related chronic diseases are treated.
- Therapeutic areas
- NeurologyOphthalmologyOther
- Modalities
- Gene therapyEpigenetic modulation
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Harvard UniversityWyss Institute for Biologically Inspired Engineering
Beyond the preview
Go deeper on AGeM Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGeM Bio.